Cathelicidin LL-37: what the research says.
Last updated May 22, 2026
The sole human cathelicidin, a 37-amino-acid amphipathic peptide cleaved from the hCAP-18 precursor by kallikrein proteases. LL-37 sits at the intersection of innate immunity and tissue repair: direct antimicrobial activity, immune cell chemotaxis, wound-healing modulation, and a tight regulatory link to vitamin D. Here is what the evidence supports, and where the boundaries are.
Regulatory notice: LL-37 is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. LL-37 is not offered by PepScribe. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including LL-37. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that LL-37’s legal status has changed or that PepScribe will offer it in the future.
What LL-37 is.
LL-37 is the active C-terminal fragment of hCAP-18 (human cationic antimicrobial protein, 18 kDa), the only cathelicidin encoded in the human genome (gene CAMP, chromosome 3p21.3). The precursor is stored in the secondary granules of neutrophils and is also expressed by epithelial cells of skin, airway, gut, and reproductive tract, plus monocytes, mast cells, and NK cells. When neutrophils degranulate or epithelial cells encounter pathogens, hCAP-18 is released and cleaved by serine proteases, primarily kallikrein 5 in skin, to liberate the 37-residue mature peptide that begins with two leucines (hence “LL-37”).
The cathelicidin family was mapped through the 1990s and early 2000s by groups including Robert Lehrer, Tomas Ganz, Birgitta Agerberth, and Robert Modlin, who established cathelicidins as a conserved arm of vertebrate innate immunity. LL-37 is unusual among antimicrobial peptides for being multifunctional: alongside direct microbial killing, it acts as a host-defense signal that recruits neutrophils, monocytes, T cells, and mast cells, modulates dendritic cell maturation, neutralizes lipopolysaccharide, and influences keratinocyte migration during wound repair.
A defining regulatory feature, established by Philip Liu, Robert Modlin, and colleagues (Science, 2006), is that the CAMP gene contains a vitamin D response element. 1,25-dihydroxyvitamin D directly upregulates LL-37 expression in macrophages and keratinocytes, linking vitamin D status to cathelicidin-mediated host defense. This axis has shaped much of the subsequent research interest in LL-37, particularly around tuberculosis, respiratory infection, and skin barrier biology.
How it works (proposed mechanisms).
Membrane disruption, broad spectrum
LL-37 is amphipathic and cationic at physiological pH. Work by Oren and Shai (1998) and subsequent biophysical studies (Henzler-Wildman et al., 2003, Biochemistry) describe a carpet-like or toroidal-pore mechanism in which the peptide binds anionic bacterial membranes, inserts into the lipid bilayer, and disrupts membrane integrity. Activity has been documented against Gram-positive and Gram-negative bacteria, enveloped viruses (including influenza A and respiratory syncytial virus), and several fungal species. Activity is reduced at physiological salt concentrations, which is one reason in vitro potency does not translate cleanly to in vivo efficacy.
Beyond microbial killing
Robert Hancock and colleagues (Bowdish et al., 2005, Journal of Immunology) reframed LL-37 as a host-defense peptide whose immunomodulatory role may dominate over direct killing in physiological conditions. LL-37 binds the formyl peptide receptor FPR2 (also called FPRL1) to recruit neutrophils, monocytes, and T cells. It neutralizes lipopolysaccharide, dampens excessive TLR4 signaling, modulates dendritic cell differentiation, and influences cytokine output. The net immune effect is context-dependent, which is central to why the peptide can be both protective and pathogenic.
Re-epithelialization and angiogenesis
Heilborn et al. (2003, Journal of Investigative Dermatology) showed that LL-37 is upregulated at the wound edge and that blocking it impairs re-epithelialization in human skin explants. Koczulla et al. (2003, Journal of Clinical Investigation) demonstrated angiogenic activity: LL-37 stimulates endothelial proliferation and capillary formation through FPR2 signaling. The peptide also promotes keratinocyte migration and modulates collagen deposition. Interest in LL-37 as a topical wound agent derives from this body of work.
The CAMP gene response element
Liu et al. (2006, Science), with Robert Modlin’s group at UCLA, identified a vitamin D response element in the CAMP promoter and showed that 1,25-dihydroxyvitamin D triggers LL-37 expression in macrophages challenged with Mycobacterium tuberculosis. Gombart et al. (2005, FASEB Journal) confirmed the regulatory architecture. This is the mechanistic basis for the long-standing observation that vitamin D deficiency associates with increased susceptibility to tuberculosis and several respiratory infections, and it is why much of the modern LL-37 literature is intertwined with vitamin D biology.
LL-37 is a multifunctional molecule whose effect depends heavily on concentration, local tissue environment, and the disease context. Therapeutic translation is constrained by that complexity, not by an absence of mechanism.
What the research suggests.
The LL-37 literature is large (thousands of indexed publications) and spans dermatology, pulmonology, infectious disease, oncology, and immunology. The following are the areas with the densest mechanistic and translational data.
Rosacea and overexpression
Yamasaki and Gallo (2009, Nature Medicine) identified abnormal LL-37 processing as a driver of rosacea pathology. In affected skin, kallikrein 5 activity is elevated and produces aberrant LL-37 fragments that trigger inflammation and vascular dysfunction. This work established LL-37 as a cause-and-effect contributor to rosacea, not a bystander, and informed subsequent therapeutic strategies aimed at controlling cathelicidin processing rather than augmenting it. It is also a reminder that more LL-37 is not categorically “better” in skin biology.
Atopic dermatitis (relative deficiency)
Ong et al. (2002, New England Journal of Medicine), with Donald Leung’s group, reported that LL-37 and human beta-defensin-2 are deficient in lesional atopic dermatitis skin compared with psoriasis. That relative deficiency is one mechanistic explanation for the elevated rate of bacterial and viral skin infection (including eczema herpeticum) seen in AD patients. The contrast with rosacea, where LL-37 is overexpressed and pathogenic, illustrates how cathelicidin biology runs in both directions.
Wound healing research
Beyond the foundational Heilborn and Koczulla papers, several groups have studied topical and engineered LL-37 analogs in chronic wound models. Grnberg et al. (2014, Wound Repair and Regeneration) reported topical LL-37 benefits in venous leg ulcer pilot work. Engineered analogs designed to preserve antimicrobial activity at physiological salt concentrations remain in preclinical and early clinical development. No LL-37 product has full regulatory approval as of 2026.
Respiratory infection and COPD
Jiang et al. (2012) and others have documented LL-37 alterations in chronic obstructive pulmonary disease, cystic fibrosis, and bronchiectasis, where airway cathelicidin balance shifts with chronic infection and inflammation. The vitamin D / LL-37 / tuberculosis axis (Liu et al., 2006) and observational links between vitamin D status and respiratory infection severity are part of the same mechanistic story. Therapeutic exploitation of this axis is mostly studied through vitamin D supplementation, not direct LL-37 dosing.
Antiviral and COVID-19 work
In vitro studies have reported LL-37 activity against several enveloped viruses, including influenza A (Tripathi et al., 2013, PLOS ONE) and respiratory syncytial virus (Currie et al., 2013, PLOS ONE). During the COVID-19 pandemic, multiple groups examined LL-37 binding to SARS-CoV-2 spike protein and ACE2 in computational and biochemical models. None of this has translated into approved therapeutics, and headline claims about LL-37 “treating” COVID-19 outran the data.
Oncology (genuinely mixed signal)
The cancer literature on LL-37 is bidirectional. Pro-tumor effects have been reported in ovarian (Coffelt et al., 2008, International Journal of Cancer), lung, and breast cancer models, where LL-37 promotes proliferation, migration, or angiogenesis. Anti-tumor effects have been reported in colon and gastric cancer models (Wu et al., 2010, Carcinogenesis), where LL-37 induces apoptosis. The direction depends on tumor type, receptor profile, and microenvironment. This is not a clean therapeutic story in either direction.
Off-label use in chronic infection
Some integrative and Lyme-literate clinicians have applied compounded LL-37 off-label in chronic infection, biofilm-associated, and persistent immune dysregulation contexts. This use is not supported by randomized clinical trials and rests on mechanistic plausibility plus case-series experience. The evidence base for this application is weaker than for the rosacea or wound healing literature.
Administration (research context).
Research-grade and compounded LL-37 has been studied in subcutaneous injection, topical formulation (for skin and wound applications), nebulized aerosol (for airway research), and in engineered analog forms designed to resist proteolysis and retain activity in serum. There is no internationally standardized clinical dosing protocol, because there is no approved LL-37 drug product.
Half-life of native LL-37 in serum is short due to proteolytic degradation and binding to apolipoprotein A-I and other carrier proteins. Many of the translational programs in development have focused on stabilized analogs or delivery systems rather than native peptide.
This is research context, not prescribing guidance. PepScribe does not currently offer LL-37 and this information should not be interpreted as a dosing recommendation.
Side effects & safety considerations.
LL-37 has documented dual-edged biology. The same properties that make it a host-defense effector also make it a contributor to inflammatory pathology in several skin and autoimmune conditions.
Cytotoxicity at high concentration
In vitro, LL-37 is cytotoxic to mammalian cells at concentrations above roughly 10 to 25 micromolar, with the threshold varying by cell type and conditions (Johansson et al., 1998, Journal of Biological Chemistry). Therapeutic windows are narrow, which is one of the central engineering problems for any LL-37-based drug development.
Inflammatory and autoimmune signaling
Lande et al. (2007, Nature) showed that LL-37 binds self-DNA and drives plasmacytoid dendritic cell activation through TLR9, a mechanism implicated in psoriasis pathogenesis. Subsequent work has linked LL-37 to autoantigen formation in lupus and to mast cell activation. Overexpression is not a benign state.
Dermatologic risk
Given the rosacea and psoriasis associations (Yamasaki et al., Lande et al.), systemic or sustained augmentation of LL-37 carries a plausible risk of triggering or worsening inflammatory skin disease in susceptible individuals. Patient selection matters more here than for many other peptides.
Limited human RCT data
Despite the depth of the basic science literature, randomized controlled trials of therapeutic LL-37 in humans are limited and small. Long-term safety data for chronic dosing in non-research populations does not exist at the scale that would support definitive clinical guidance.
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.
Legal status.
Cathelicidin LL-37 is not an FDA-approved drug. There is no marketed LL-37 pharmaceutical for any indication in the United States.
LL-37 is named on the FDA Category-unclassified peptide list released April 15, 2026, which identifies bulk substances removed from the explicit Category 2 prohibited list but not affirmatively placed on Category 1. Pending PCAC review (most by July 2026, the remainder by the end of February 2027), LL-37 sits in a regulatory regulatory ambiguity where some 503A compounding pharmacies are operating on the theory that removal from Category 2 lifts the prohibition, while final FDA disposition is not settled.
Until that review concludes, LL-37 is treated by PepScribe as a consultation- first peptide. No PepScribe commercial surface markets LL-37 by name. A clinician evaluates whether LL-37 or any alternative is appropriate during the consultation, in the context of the patient’s infection or immune history, dermatologic risk, and current evidence base.
NAD+
Supports cellular energy production, mitochondrial function, and the immune metabolism pathways that underlie host defense. Physician-prescribed and delivered to your door.
Get startedSermorelin
Growth hormone-releasing peptide. GH supports tissue repair, immune function, and the deep sleep architecture in which much immune housekeeping happens. Physician-prescribed.
Get startedDeep dives
More on LL-37.
Research-backed articles covering specific topics in depth.
Explore clinician-led options.
LL-37 sits in an FDA regulatory ambiguity with dual-edged immune biology. PepScribe routes you through a clinician consultation that evaluates the full picture: infection or immune context, dermatologic risk, and current evidence.